The West Coast Symposium on Expanded Access

Expanded Access 2018

Click on the presentation title to view the presentation

8:30 a.m. – 8:50 a.m.

Welcome and Introduction by Chairperson

  • Jess Rabourn, Founder/CEO, WideTrial, Inc.

8:50 a.m. – 9:50 a.m.

The Foundations of EAPs

  • David Farber, Senior Partner, King & Spalding
  • Karen Frascello, Vice President of Business Development, Caligor

10:15 a.m. – 12: 15 p.m.

Handling the Challenges of EAPs

  • Heather Manna, Associate Director, Expanded Access, Tesaro Bio, Inc.
  • Tom Watson, Executive Vice President Early Access Programs, Bionical Group
  • Hank Mansbach, MD, VP Clinical Development, Ultragenyx
  • Kevin Weatherwax, Adjunct Associate Clinical Professor, Co-Chair, Expanded Access Oversight Committee, University of Michigan Medical System
  • Karen Frascello, Vice President of Business Development, Caligor
  • David Farber, Senior Partner, King & Spalding

1:30 p.m. – 2:30 p.m.

Maximizing the Value of EAPs

  • Hank Mansbach, MD, VP Clinical Development, Ultragenyx
  • Jess Rabourn, Founder/CEO, WideTrial, Inc.
  • Kevin Weatherwax, Adjunct Associate Clinical Professor, Co-Chair, Expanded Access Oversight Committee, University of Michigan Medical System

2:30 p.m. – 3:15 p.m.

Can EAPs Improve the Drug Development Process in Breakthrough Diseases?

3:30 p.m. – 5:00 p.m.

New Business Models for Inclusivity, Wider Access to Patients, and Data Utilization

  • Heather Manna, Associate Director, Expanded Access, Tesaro Bio, Inc.
  • Tom Watson, Executive Vice President Early Access Programs, Bionical Group
  • Kevin Weatherwax, Adjunct Associate Clinical Professor, Co-Chair, Expanded Access Oversight Committee, University of Michigan Medical System
  • Jess Rabourn, Founder/CEO, WideTrial, Inc.